Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

7792 ARTÍCULOS , VIENDO DEL 4696 AL 4710

Imaging of Proteinopathies in the Brains of Parkinsonian Disorders

Higuchi M.

Cells. 2025 Sep 10;14(18):1418. doi: 10.3390/cells14181418.

Emerging Clinical Role of Tavapadon, a Novel Dopamine Partial Agonist, in the Treatment of Parkinson's Disease

Kaye AD, Ford BM, Abbott BM, Broocks KM, Novacic S, Shekoohi S.

Diseases. 2025 Sep 2;13(9):290. doi: 10.3390/diseases13090290.

Mitochondria-Associated Membrane Dysfunction in Neurodegeneration and Its Effects on Lipid Metabolism, Calcium Signaling, and Cell Fate

Truong TT, Singh AA, Bang NV, Vu NMH, Na S, Choi J, Oh J, Mondal S.

Membranes (Basel). 2025 Aug 31;15(9):263. doi: 10.3390/membranes15090263.

Amyloid-like Structures in Marine Adhesive Proteins

Santos MR, Henriques BJ, Santos R.

Mar Drugs. 2025 Sep 19;23(9):363. doi: 10.3390/md23090363.

Neuroimmune crosstalk in Parkinson's disease: the pivotal role of microglia and infiltrating T cells

Li X, Sun W, Chen W, Wang N, Wang S.

Mol Biol Rep. 2025 Sep 26;52(1):950. doi: 10.1007/s11033-025-11067-0.

Targeting Metabolic Dysfunction in Parkinson's Disease: The Role of GLP-1 Agonists in Body Weight Regulation and Neuroprotection

Aviles-Olmos I, Espinoza-Vinces C, Portugal LR, Luquin MR.

Curr Diab Rep. 2025 Sep 26;25(1):49. doi: 10.1007/s11892-025-01606-1.

Seed Amplification Assays as Powerful Tools for Detecting Peripheral Biomarkers in Prion-Like Diseases

Dellarole IL, Lombardo A, Ciullini A, Cazzaniga FA, Domina R, Bacınoğlu MB, Moda F.

Subcell Biochem. 2025;112:293-320. doi: 10.1007/978-3-031-97055-9_13.

Neuroprotective and Neurotrophic Effects of Astaxanthin on the Brain

Yook JS, Soya H.

Adv Neurobiol. 2025;44:317-334. doi: 10.1007/978-981-95-0066-6_17.

Comparative analysis of trunk sensor placement in people with and without Parkinson's disease

Sotirakis C, Pelliet A, Conway N, FitzGerald J, Antoniades C.

J Biomech. 2025 Nov;192:112975. doi: 10.1016/j.jbiomech.2025.112975. Epub 2025 Sep 19.

Hypoxic conditioning in Parkinson's disease: randomized controlled multiple N-of-1 trials

Janssen Daalen JM, Meinders MJ, Giardina F, Mathur S, Ainslie PN, Thijssen DHJ, Bloem BR.

Nat Commun. 2025 Sep 26;16(1):8469. doi: 10.1038/s41467-025-63324-2.

Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease and Other Neurological Disorders: A Comprehensive Review

Abdalla M, Ibrahim M, Alkorbi N, Alkuwari S, Pedersen S, Rathore HA.

Biomedicines. 2025 Aug 26;13(9):2073. doi: 10.3390/biomedicines13092073.

Gut Microbiota in Psychiatric and Neurological Disorders: Current Insights and Therapeutic Implications

Dziedziak M, Mytych A, Szyller HP, Lasocka M, Augustynowicz G, Szydziak J, Hrapkowicz A, Dyda M, Braksator J, Pytrus T.

Biomedicines. 2025 Aug 29;13(9):2104. doi: 10.3390/biomedicines13092104.

Artificial Intelligence-Driven Neuromodulation in Neurodegenerative Disease: Precision in Chaos, Learning in Loss

Calderone A, Latella D, La Fauci E, Puleo R, Sergi A, De Francesco M, Mauro M, Foti A, Salemi L, Calabrò RS.

Biomedicines. 2025 Aug 30;13(9):2118. doi: 10.3390/biomedicines13092118.

Recent Advances in Parkinson's Disease Research: From Pathophysiology to Novel Therapeutic Approaches

Yeo S.

Biomedicines. 2025 Sep 17;13(9):2283. doi: 10.3390/biomedicines13092283.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias